News

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.

Johnson & Johnson submits a supplemental New Drug Application to the FDA for the approval of esketamine as a monotherapy for adults with treatment-resistant depression.

Bludorn joins Lungcast to review the increasing effects and signs of heat-related illness amid record-high temperatures.

The approval was based on the clinical, non-clinical, and analytical data proving eculizumab-aagh's bioequivalence to the reference drug.

These data suggest that the introduction of the concept of circadian syndrome contributes to greater understanding of risk management for those with psoriasis.

The analysis of NHANES data found individuals with viral hepatitis and NAFLD as well as lower income and no college education were at a greater risk of mortality.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.

Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.

A new study found individuals with depression and anxiety have a high prevalence of medical debt.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.

Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.

RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.